Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.79 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.79 |
| ▸ | SHBG | P04278 | 4/20 | 0.79 |
| ▸ | TSHR | P16473 | 3/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.79 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.79 |
| ▸ | FNTA | P49354 | 5/20 | 0.72 |
| ▸ | FNTB | P49356 | 5/20 | 0.72 |
| ▸ | BLM | P54132 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | AR | P10275 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625974 | 1.00 | HSD17B10 (0.79) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 | |
| SCHEMBL11615772 | 0.92 | HSD17B10 (0.76) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 | |
| SCHEMBL11885536 | 0.91 | HSD17B10 (0.79) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 | |
| SCHEMBL143924 | 0.91 | HSD17B10 (0.79) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 | |
| SCHEMBL19327145 | 0.91 | HSD17B10 (0.79) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 | |
| Cortisone SCHEMBL6535496 | 0.89 | HSD17B10 (1.00) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 | |
| SCHEMBL6544531 | 0.89 | HSD17B10 (0.85) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 | |
| Cortisone SCHEMBL13332835 | 0.89 | HSD17B10 (1.00) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 | |
| Cortisone SCHEMBL4888 | 0.89 | HSD17B10 (1.00) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 | |
| Cortisone SCHEMBL9926754 | 0.89 | HSD17B10 (1.00) | HSD17B10SERPINA6LMNANR3C1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928078-B2 | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2011-04-19 | — | — | US | disclosed |
| US-7923441-B2 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2011-04-12 | — | — | US | disclosed |
| US-7776846-B2 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2010-08-17 | — | — | US | disclosed |
| EP-1351973-B1 | CONJUGATES OF IMMUNE CELL SPECIFIC MACROLIDE COMPOUNDS WITH ANTI-INFLAMMATORY COMPOUNDS FOR IMPROVED CELLULAR TARGETING OF ANTI-INFLAMMATORY THERAPY | GLAXOSMITHKLINE ZAGREB (HR) | 2010-03-31 | — | — | EP | disclosed |
| EP-1653974-B1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR NICHOLAS S (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090239833-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR LABORATORIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-7560448-B2 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2009-07-14 | — | — | US | disclosed |
| US-20090105163-A1 | Conjugates of Immune Cell Specific Macrolide Compounds with Anti-Inflammatory Compounds for Improved Cellular Targeting of Anti-Inflammatory Therapy | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2009-04-23 | — | — | US | disclosed |
| US-7446097-B2 | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O (HR) | 2008-11-04 | — | — | US | disclosed |
| US-20080261930-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR LABORATORIES, INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1658083-B1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR NICHOLAS S (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1658083-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR, Nicholas S. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1653974-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR, Nicholas S. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050026892-A1 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20050020551-A1 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2005000317-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR NICHOLAS S (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004112800-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR NICHOLAS S (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040198677-A1 | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2004-10-07 | — | — | US | disclosed |
| EP-0902789-B1 | ANDROSTENE DERIVATIVES | SOFT DRUGS INC (US) | 2002-01-23 | — | — | EP | disclosed |
| US-5646136-A | ADMINISTERING STEROID HAVING ANGIOSTATIC ACTIVITY TO A PATIENT | DUKE UNIVERSITY (US) | 1997-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020551-A1 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | NR3C1, NR3C2, HSD17B7 | HSD17B10 131/4885SERPINA6 20/4885LMNA 3415/4885 |
| US-20080261930-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | NR3C1, NR3C2, HSD17B7 | HSD17B10 131/4885SERPINA6 20/4885LMNA 3415/4885 |
| US-20040198677-A1 | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | CD14, CD40, MYD88 | HSD17B10 841/4885SERPINA6 422/4885LMNA 4100/4885 |
| US-20090105163-A1 | Conjugates of Immune Cell Specific Macrolide Compounds with Anti-Inflammatory Compounds for Improved Cellular Targeting of Anti-Inflammatory Therapy | CD14, CD40, MYD88 | HSD17B10 841/4885SERPINA6 422/4885LMNA 4100/4885 |
| US-20050026892-A1 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | OXER1, ELOVL6, ELOVL3 | HSD17B10 254/4885SERPINA6 209/4885LMNA 1749/4885 |
| US-20090239833-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | OXER1, ELOVL6, ELOVL3 | HSD17B10 254/4885SERPINA6 209/4885LMNA 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.